Shopping Cart
- Remove All
Your shopping cart is currently empty
3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid that exhibits good tolerance and good intestinal absorption when administered orally.3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) can undergo enzymatic isomerization in the intestines and the 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) undergoes enzymatic isomerization in the intestine and liver and produces UDCA.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $34 | In Stock | |
| 5 mg | $80 | In Stock | |
| 10 mg | $139 | In Stock | |
| 25 mg | $272 | In Stock | |
| 50 mg | $419 | In Stock | |
| 100 mg | $612 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $89 | In Stock |
| Description | 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) is a bile acid that exhibits good tolerance and good intestinal absorption when administered orally.3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) can undergo enzymatic isomerization in the intestines and the 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) undergoes enzymatic isomerization in the intestine and liver and produces UDCA. |
| In vitro | METHODS: Hep G2 cells were treated with 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) (100 μM) and ethanol (80 μM) to investigate the effects of 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) and ethanol on Hep G2 cells. The cytotoxic effects of 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) and ethanol on Hep G2 cells were investigated, as well as the interactions between them. RESULTS 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) did not show any cytotoxic effects and could be cytoprotective against ethanol-induced cell damage. [4] Translated with DeepL.com (free version) |
| In vivo | METHODS: 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) or UDCA (2.5 g/kg, orally, for 3 weeks) were given to rats , respectively , to compare the metabolism of UDCA and 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) in experimental cholestasis and the effects on cholestasis in rats. RESULTS3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) was completely converted to UDCA in the liver; cholestasis and cholestatic bile acids were identical after intraduodenal administration of either compound. Oral administration of UDCA or 3β-Ursodeoxycholic acid (Isoursodeoxycholic acid) significantly improved hepatic biochemistry in chronic cholestasis, but not clinical and histologic parameters. [1] Translated with DeepL.com (free version) |
| Synonyms | Isoursodeoxycholic acid |
| Molecular Weight | 392.57 |
| Formula | C24H40O4 |
| Cas No. | 78919-26-3 |
| Smiles | C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@](C[C@@H]3O)(C[C@@H](O)CC4)[H])(CC1)[H])[H])(CC[C@@]2([C@@H](CCC(O)=O)C)[H])[H] |
| Relative Density. | 1.128 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90.0 mg/mL (229.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.41 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.